US OptionsDetailed Quotes
IRON241220P60000
- 1.65
- -0.85-34.00%
15min DelayClose Nov 25 16:00 ET
1.65High1.55Low
1.55Open2.50Pre Close25 Volume155 Open Interest60.00Strike Price4.04KTurnover54.70%IV9.53%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry1.65Extrinsic Value100Contract SizeAmericanOptions Type-0.2737Delta0.0366Gamma39.09Leverage Ratio-0.0607Theta-0.0117Rho-10.70Eff Leverage0.0554Vega
Disc Medicine Stock Discussion
Sign in to post a comment
$Kazia Therapeutics (KZIA.US)$ $Disc Medicine (IRON.US)$ $Air Transport Services (ATSG.US)$ $Globalstar (GSAT.US)$ $Tenaya Therapeutics (TNYA.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Hanryu Holdings (HRYU.US)$ $Vast Renewables (VSTE.US)$ $Neurogene (NGNE.US)$ $Advent Technologies (ADN.US)$ $Staffing 360 Solutions (STAF.US)$ $Nuwellis (NUWE.US)$ $Simpple (SPPL.US)$
📊⚡️📊
📊⚡️📊
2
3
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
16
3
$Disc Medicine (IRON.US)$ easy money
2
$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
38
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
28
1
$Auddia (AUUD.US)$ $Charles River (CRL.US)$ $Devon Energy (DVN.US)$ $Eastside Distilling (EAST.US)$ $Finch Therapeutics (FNCH.US)$ $Forza X1 (FRZA.US)$ $iBio Inc (IBIO.US)$ $Disc Medicine (IRON.US)$ $Leju Holdings (LEJU.US)$ $Lumen Technologies (LUMN.US)$ $MediaCo (MDIA.US)$ $The OLB Group (OLB.US)$ $Oracle (ORCL.US)$ $Rockwell Medical (RMTI.US)$ $Target (TGT.US)$
$ArcBest (ARCB.US)$ initiated at buy by Jefferies, announced target price at $110.00.
$Saia (SAIA.US)$ initiated at buy by Jefferies, announced targe price at $350.00.
$AutoZone (AZO.US)$ was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00.
$Oracle (ORCL.US)$ was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00.
$BILL Holdings (BILL.US)$ was downg...
$Saia (SAIA.US)$ initiated at buy by Jefferies, announced targe price at $350.00.
$AutoZone (AZO.US)$ was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00.
$Oracle (ORCL.US)$ was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00.
$BILL Holdings (BILL.US)$ was downg...
16
$Disc Medicine (IRON.US)$ no attention very recent rs and it flies
No comment yet
far008 : $Vast Renewables (VSTE.US)$ has no short shares. we should see an uptick
103822628 : Sorry , unusual volume ticks means wat?
Stock_Drift OP 103822628 : Look at the volume. It’s unusual